PharmaGraphX

Log in Get Started

Lemborexant

Dayvigo

Uncategorized

Standard

Half-life

17-19 hours

Protein Binding

94%

Metabolized By

N/A

External

Drugs.com

Clinical alerts

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Blocks orexin OX1R and OX2R receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Alcohol Use Disorder
·Parkinson's Disease
·Insomnia
·Motor Disorder
·Cirrhosis

Interactions

No curated interaction pairs are recorded for Lemborexant. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Somnolence
Headache
Sleep paralysis

Food, alcohol & herbal

Food

High-fat meal delays absorption

Alcohol · major

Additive CNS depression

Pharmacokinetics

Half-life: 17-19 hours
Protein binding: 94%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Lemborexant. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement